CSL BEHRING LLC for CSL BEHRING LLC
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 3rd Quarter - Report (this page) | Oct 1, 2014 | $170,000 | Replaced |
| 3rd Quarter - Amendment | Oct 1, 2014 | $170,000 | Yes |
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Preserving Access to Orphan Drugs Act (HR 2315/S 1128)- legislation excluding all therapies that solely treat orphan conditions from the annual pharmaceutical fee. Orphan designation - the need to delink clinical superiority from designation Preservation of the Orphan Drug Tax Credit
| Lobbyist | Covered position, as disclosed |
|---|---|
| BRIAN R. BULLARD | Sr. Manager, Federal Government Affairs |
| PATRICK COLLINS | Director, Healthcare Policy and External Affairs |
| DENNIS JACKMAN | Sr. Vice President, Healthcare Policy and External Affairs |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.